TY - JOUR
T1 - Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models
T2 - Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network
AU - Cucurull-Sanchez, Lourdes
AU - Chappell, Michael J.
AU - Chelliah, Vijayalakshmi
AU - Amy Cheung, S. Y.
AU - Derks, Gianne
AU - Penney, Mark
AU - Phipps, Alex
AU - Malik-Sheriff, Rahuman S.
AU - Timmis, Jon
AU - Tindall, Marcus J.
AU - van der Graaf, Piet H.
AU - Vicini, Paolo
AU - Yates, James W.T.
N1 - Funding Information:
Funding. The authors acknowledge funding support from the Engineering and Physical Sciences Research Council and Medical Research Council for the UK Quantitative Systems Pharmacology Network (EP/N005481/1). R.S.M.-S. has been supported by the Biotechnology and Biological Sciences Research Council with a MultiMod grant BB/N019482/1 and European Molecular Biology Laboratory core funding.
Publisher Copyright:
© 2019 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.
PY - 2019/5
Y1 - 2019/5
N2 - The lack of standardization in the way that quantitative and systems pharmacology (QSP) models are developed, tested, and documented hinders their reproducibility, reusability, and expansion or reduction to alternative contexts. This in turn undermines the potential impact of QSP in academic, industrial, and regulatory frameworks. This article presents a minimum set of recommendations from the UK Quantitative and Systems Pharmacology Network (UK QSP Network) to guide QSP practitioners seeking to maximize their impact, and stakeholders considering the use of QSP models in their environment.
AB - The lack of standardization in the way that quantitative and systems pharmacology (QSP) models are developed, tested, and documented hinders their reproducibility, reusability, and expansion or reduction to alternative contexts. This in turn undermines the potential impact of QSP in academic, industrial, and regulatory frameworks. This article presents a minimum set of recommendations from the UK Quantitative and Systems Pharmacology Network (UK QSP Network) to guide QSP practitioners seeking to maximize their impact, and stakeholders considering the use of QSP models in their environment.
KW - Humans
KW - Models, Biological
KW - Parathyroid Hormone/adverse effects
KW - Practice Guidelines as Topic
KW - Reproducibility of Results
KW - Systems Biology/standards
KW - United Kingdom
UR - http://www.scopus.com/inward/record.url?scp=85064573186&partnerID=8YFLogxK
U2 - 10.1002/psp4.12381
DO - 10.1002/psp4.12381
M3 - Article
C2 - 30667172
AN - SCOPUS:85064573186
SN - 2163-8306
VL - 8
SP - 259
EP - 272
JO - CPT: Pharmacometrics and Systems Pharmacology
JF - CPT: Pharmacometrics and Systems Pharmacology
IS - 5
ER -